Porex Corporation Announces Litigation Settlement with MicroPore

FAIRBURN, Ga., April 23 /PRNewswire/ -- Porex Corporation ("Porex"), a portfolio company of Los Angeles-based investment firm Aurora Capital Group, today announced that it has reached a settlement agreement with MicroPore Plastics, Inc. ("MicroPore") that ends all pending intellectual property litigation between the parties.  As part of the settlement agreement, Porex has taken ownership of MicroPore, including its intellectual property, technology and operations.  Additional settlement details were not disclosed.

"We are pleased to have resolved this matter in a way that best serves both companies' customers and allows Porex and MicroPore professionals to focus their energies on Porex's mission: innovating in partnership with our customers," said William Midgette, President and Chief Executive Officer of Porex. "Porex's commitment to growth, the continuous enhancement of our materials science expertise and facilitating unique capabilities for our customers' products has made it the leader in porous plastics. We welcome MicroPore's talented employees and look forward to our next phase of progress." The Porex and MicroPore management teams are working collaboratively to ensure a seamless integration of the two companies. 

Intellectual property and R&D are critical components of Porex's business and the Company will continue to vigorously defend its intellectual property rights.

About Porex Corporation

Founded in 1961 and based in Fairburn, GA, Porex is the leading global developer, manufacturer and distributor of porous plastic products.  The Company primarily serves the healthcare and surgical end markets, and also supports high-performance applications in the consumer and industrial sectors.  Porex products serve filtration, venting, wicking, and diffusing functions in applications such as blood filters, catheter vents, fuel filters, writing instrument tips and consumable diagnostic tests.  In addition, through its MEDPOR brand, Porex's surgical products are the first FDA-cleared porous plastic implants for use in craniofacial and orbital reconstructive surgery.  Porex, which pioneered porous plastic technology over 40 years ago, is today widely recognized for its materials science expertise and proprietary designs which serve over 1,250 customers across more than 75 countries via operations in North America, Europe and Asia. For more information about Porex Corporation, visit www.porex.com.

SOURCE Porex Corporation